posizolid

an antitubercular agent; structure in first source

Also Known As:

AZD 2563; AZD-5847; AZD2563; AZD5847; 2-oxazolidinone, 3-(4-(1-((2S)-2,3-dihydroxy-1-oxopropyl)-1,2,3,6-tetrahydro-4-pyridinyl)-3,5-difluorophenyl)-5-((3-isoxazolyloxy)methyl)-, (5R)-

Networked: 8 relevant articles (0 outcomes, 4 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Oxazoles: 89
      - Oxazolidinones: 316
        posizolid: 8

Experts

1.	Alsultan, Abdullah: 3 articles (01/2018 - 11/2016)
2.	Boom, W Henry: 3 articles (01/2018 - 11/2016)
3.	Chheng, Phalkun: 3 articles (01/2018 - 11/2016)
4.	Diacon, Andreas H: 3 articles (01/2018 - 11/2016)
5.	Du Bois, Jeannine: 3 articles (01/2018 - 11/2016)
6.	Furin, Jennifer J: 3 articles (01/2018 - 11/2016)
7.	Johnson, John L: 3 articles (01/2018 - 11/2016)
8.	Peloquin, Charles A: 3 articles (01/2018 - 11/2016)
9.	Venter, Amour: 3 articles (01/2018 - 11/2016)
10.	van Brakel, Elana: 3 articles (01/2018 - 11/2016)

Related Diseases

1.	Multidrug-Resistant Tuberculosis (Drug-Resistant Tuberculosis) 04/01/2015 - "After decades of quiescence in the development of antituberculosis medications, bedaquiline and delamanid have been conditionally approved for the treatment of drug-resistant tuberculosis, while several other novel compounds (AZD5847, PA-824, SQ109 and sutezolid) have been evaluated in phase II clinical trials. " 01/01/2017 - "This paper is also focused on some interesting molecules in treating multidrug-resistant tuberculosis which are currently tested in clinical studies: delamanid (dihydro-nitroimidazooxazole derivative, phase III), AZD5847 (oxazolidinone derivative, phase II), pretomanid (nitroimidazole derivative, phase III), sutezolid (oxazolidinone derivative, phase II) and SQ109 (ethambutol analogue, phase II) and some prospective molecules at the level of preclinical studies e.g., CPZEN-45, SQ609 and SQ641."
2.	Pulmonary Tuberculosis 01/01/2018 - "Erratum for Alsultan et al., "Population Pharmacokinetics of AZD-5847 in Adults with Pulmonary Tuberculosis"." 10/01/2017 - "Population Pharmacokinetics of AZD-5847 in Adults with Pulmonary Tuberculosis." 11/01/2016 - "AZD5847 dosed twice daily kills tubercle bacilli in the sputum of patients with pulmonary tuberculosis and has modest early bactericidal activity. " 11/01/2016 - "Early Bactericidal Activity of AZD5847 in Patients with Pulmonary Tuberculosis." 11/01/2016 - "Groups of 15 treatment-naive, sputum smear-positive adults with pulmonary tuberculosis were randomly assigned to receive AZD5847 at one of four doses (500 mg once daily, 500 mg twice daily, 1,200 mg once daily, and 800 mg twice daily) or daily standard chemotherapy. "
3.	Tuberculosis (Tuberculoses) 10/01/2017 - "Here we describe the population pharmacokinetics (PK) of AZD-5847 in patients with tuberculosis based on a recently completed phase II study. " 07/01/2014 - "Pharmacokinetic and pharmacodynamic evaluation of AZD5847 in a mouse model of tuberculosis." 10/01/2017 - "AZD-5847 is a new oxazolidinone derivative under development for the treatment of tuberculosis (TB). " 01/01/2014 - "Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis."
4.	Latent Tuberculosis 06/01/2014 - "Here, we compared the activities of three oxazolidinones, linezolid, PNU-100480, and AZD5847, against latent tuberculosis using a simple model employing the streptomycin-starved Mycobacterium tuberculosis strain 18b. "
5.	Thrombocytopenia (Thrombopenia) 11/01/2016 - "Two serious adverse events (grade 4 thrombocytopenia and grade 4 hyperbilirubinemia) occurred in patients receiving AZD5847 at higher doses. "

Related Drugs and Biologics

1.	PNU-100480
2.	OPC-67683
3.	pretomanid
4.	Oxazolidinones (2 Oxazolidone)
5.	Oxindoles
6.	Nitroimidazoles
7.	Ethambutol (Myambutol)
8.	Anti-Bacterial Agents (Antibiotics)
9.	CPZEN-45
10.	bedaquiline (R207910)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)